2020 Fiscal Year Final Research Report
Scientific Research for the Development of Novel Therapeutics in Marfan Syndrome Targeting Endothelial Cells-derived Oxidative Stress
| Project/Area Number |
18K08097
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53020:Cardiology-related
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Keywords | 分子血管学 |
|---|
| Outline of Final Research Achievements |
We demonstrated that aberrant activation of mechanosensitive signaling in vascular endothelial cells triggered endothelial activation of xanthine oxidoreductase (XOR) and generation of reactive oxygen species (ROS), leading to progression of aneurysm formation in ascending aorta of Marfan syndrome.
There is currently no effective medical treatment, but our study highlights a drug repositioning approach using a uric acid lowering drug febuxostat as a potential therapy for Marfan syndrome.
|
| Free Research Field |
医歯薬学
|
| Academic Significance and Societal Importance of the Research Achievements |
マルファン症候群はFBN1の遺伝子異常により全身の結合組織の構造・機能破綻を来す常染色体優性の希少難治性疾患である。MFSの遺伝子変異による疾患発症の分子機序はいまだに不明な点が多く残されていたが、本研究により血管内皮におけるxanthine oxidoreductase由来の酸化ストレスがマルファン症候群における大動脈瘤の病態形成に重要な役割を果たすことが明らかとなった。Xanthine oxidoreductase阻害薬であるfebuxostatの新規治療法開発へと応用されることが期待される。
|
